{"id":"tp-53489","type":"article-newspaper","title":"Trevi Expects Q1 2027 Start for Phase 2 Non-IPF ILD-Related Chronic Cough Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53489","datePublished":"2026-11-11T02:28:32.000Z","dateModified":"2026-11-11T02:28:32.000Z","language":"en","abstract":"Trevi’s $299.4 million in cash, cash equivalents and marketable securities is expected to support key programs into 2030.","section":"Business","references":[]}